ILCA 2020 - 14th Annual Conference of the International Liver Cancer Association (Virtual Meeting)
Sep 11 - Sep 13, 2020 | MadridSpain
LARVOL is not affiliated with 14th Annual Conference of the International Liver Cancer Association (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 18 abstracts linked to Trials
[VIRTUAL] SEQUENTIAL TREATMENT WITH SORAFENIB FOLLOWED BY REGORAFENIB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC): INTERIM ANALYSIS OF THE OBSERVATIONAL REFINE STUDY
[VIRTUAL] RAMUCIRUMAB FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND ELEVATED ALPHA FETOPROTEIN FOLLOWING A NON-SORAFENIB BASED SYSTEMIC THERAPY: INTERIM RESULTS FROM AN EXPANSION COHORT OF THE PHASE 3 REACH-2 STUDY
[VIRTUAL] OUTCOMES FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B LIVER FUNCTION IN THE PHASE 3 CELESTIAL STUDY OF CABOZANTINIB VERSUS PLACEBO
[VIRTUAL] POSTPROGRESSION SURVIVAL AFTER LENVATINIB TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA
[VIRTUAL] EXPOSURE-RESPONSE ANALYSIS FOR NIVOLUMAB + IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
[VIRTUAL] SORAFENIB (SOR) COMBINED WITH NIVOLUMAB (NIVO) IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC): SAFETY AND EFFICACY IN A DOSE ESCALATION COHORT
[VIRTUAL] EFFICACY AND SAFETY OF LENVATINIB AS A SALVAGE THERAPY OF TRANSARTERIAL TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
[VIRTUAL] EFFECT OF PEMBROLIZUMAB (PEMBRO) ON HEPATITIS B VIRUS (HBV) LOAD AND AMINOTRANSFERASE (ALT) LEVELS IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) IN KEYNOTE-224 AND KEYNOTE-240
[VIRTUAL] ALPHA-FETOPROTEIN (AFP) KINETICS AS A POTENTIAL SURROGATE BIOMARKER IN PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ATEZOLIZUMAB (ATEZO) + BEVACIZUMAB (BEV)
[VIRTUAL] PROTON BEAM RADIOTHERAPY VERSUS RADIOFREQUENCY ABLATION TREATMENT IN PATIENTS WITH RECURRENT HEPATOCELLULAR CARCINOMA: A RANDOMIZED CONTROLLED PHASE 3 NON-INFERIORITY APROH TRIAL
[VIRTUAL] RADIOLOGICAL AND PATHOLOGICAL RESPONSE TO NEOADJUVANT NIVOLUMAB IN PATIENTS WITH BCLC A HCC TREATED BY CURATIVE PERCUTANEOUS IRREVERSIBLE ELECTROPORATION: PRELIMINARY REPORT FROM THE FRENCH MULTICENTRE PHASE 2 NIVOLEP TRIAL.
[VIRTUAL] THE NOVEL REGIMEN OF TREMELIMUMAB IN COMBINATION WITH DURVALUMAB PROVIDES A FAVORABLE SAFETY PROFILE AND CLINICAL ACTIVITY FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC)
[VIRTUAL] PEMBROLIZUMAB IN COMBINATION WITH GEMCITABINE AND CISPLATIN FOR THE TREATMENT OF ADVANCED BILIARY TRACT CANCER: PHASE 3 KEYNOTE-966 TRIAL IN PROGRESS
[VIRTUAL] LEAP-012: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB PLUS LENVATINIB IN COMBINATION WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA (HCC) NOT AMENABLE TO CURATIVE TREATMENT
[VIRTUAL] A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF TRANSARTERIAL CHEMOEMBOLIZATION COMBINED WITH CONCURRENT DURVALUMAB FOLLOWED BY DURVALUMAB OR DURVALUMAB PLUS BEVACIZUMAB THERAPY IN PATIENTS WITH LOCOREGIONAL HEPATOCELLULAR CARCINOMA (HCC): EMERALD-1